Syndax is hit with a setback during the ASCO preview round as lead drug flops in mid-stage study
Let’s add one more big loser to the lengthy roster of wins and defeats during the ASCO preview round.
Syndax Pharmaceuticals shares $SNDX were …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
